1. Department of Pharmacy, Jinshan Hospital, Fudan University, Shanghai 201508, China;
2. Center Laboratory, Jinshan Hospital, Fudan University, Shanghai 201508, China;
3. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;
4. Department of General Surgery, Jinshan Hospital, Fudan University, Shanghai 201508, China;
5. Department of Radiation Oncology, University of Würzburg, D-97080 Würzburg, Germany
Colorectal cancer (CRC) is the third most common cancer disease. Here we examined Nampt expression in patients with CRC and the effect of Nampt on cell viability in CRC cells. Nampt protein was overexpressed in colorectal adenoma as well as colorectal carcinoma. The immunoreactive staining of Nampt was negative in the adjacent normal colorectal tissue, weak in colorectal adenoma, and strong in colorectal carcinoma, which may represent tumor progression. Further evaluation of clinical data showed that Nampt expression was not correlated with the clinicopathological characteristics of CRC. Additionally, our in vitro studies demonstrated that Nampt promotes CRC cell viability, whereas the Nampt inhibitor FK866 suppressed CRC cell viability, which was in concordance with the previous studies in other cancer cells. Treatment with Nampt-siRNA reduced the Nampt protein expression resulting in the inhibition of the cell viability of HCT116 and Caco2. Thus, the involvement of Nampt in cell growth indicates that Nampt may play an important role in colorectal tumorigenesis. As a consequence, our results suggest that Nampt may be considered as a progression marker of colorectal tumor and a potentially therapeutic target for the treatment of CRC.
Keywords: Nampt, visfatin, PBEF, tumor biomarker, adenocarcinoma, cell proliferation